What is the revenue and EPS growth rate for Royalty Pharma year over year?

What does Royalty Pharma do and what are its main business segments?

What were the key takeaways from Royalty Pharma’s earnings call?

What is the market's earnings forecast for Royalty Pharma next quarter?

What is Royalty Pharma's latest dividend and current dividend yield?

What were the key takeaways from Royalty Pharma's earnings call?

What is Royalty Pharma's gross profit margin?

What factors drove the changes in Royalty Pharma's revenue and profit?

- **Revenue Growth**: Q3 portfolio receipts up 11% to $814 million, with full-year guidance raised to $3.2 billion-$3.25 billion (14%-16% growth). 
- **Strategic Acquisitions**: $1.26 billion invested in three high-impact deals (Imdelltra, Amvuttra, obexelimab) with low double-digit IRRs. 
- **Pipeline Expansion**: 17 therapies in development, with six Phase III readouts expected in 2025-2026. 
- **Financial Strength**: 81% cash flow margin, $9.2 billion investment-grade debt, and $1.5 billion returned to shareholders. 
- **China and Obesity Focus**: Actively exploring synthetic royalty opportunities in China and obesity, with disciplined capital allocation.

**【CEO Summary Section】**
- Royalty Pharma reported 11% growth in portfolio receipts for Q3 2025, driven by strong performance across its diversified portfolio. 
- The company deployed $1 billion in new royalty transactions during the quarter, including a $950 million deal for Amgen's Imdelltra and a $310 million acquisition of Alnylam's Amvuttra royalty. 
- Full-year 2025 portfolio receipts guidance was raised to $3.2 billion-$3.25 billion, reflecting 14%-16% year-over-year growth. 
- Return on invested capital (ROIC) for the trailing 12 months was 15.7%, and return on invested equity (ROE) was 22.9%, demonstrating consistent value creation. 

**【Marshall Urist - Deal Activity】**
- Acquired a 7% royalty on Amgen's Imdelltra for $950 million, with potential upside from Phase III expansion into newly diagnosed patients. 
- Purchased a 1% royalty on Alnylam's Amvuttra for $310 million, expecting low double-digit IRR despite competition from nucresiran. 
- Entered a $300 million synthetic royalty agreement with Zenas Biopharma for obexelimab, targeting IgG4-related disease with Phase III readouts expected in late 2025. 

**【Chris Hite - Development Pipeline】**
- Expanded the development-stage pipeline to 17 therapies, with 3 Phase III readouts expected in 2025-2026 (deucrictibant, obexelimab, pelacarsen). 
- 86% of capital at work is allocated to approved products, with only 11% in development-stage investments, mitigating risk. 
- Synthetic royalties accounted for $1.8 billion of 2025 capital deployment, up from $1.2 billion in 2024. 

**【Terry Coyne - Financial Performance】**
- Q3 portfolio receipts reached $814 million, up 11% year-over-year, with operating costs at 4.2% of receipts. 
- Portfolio cash flow margin was 81%, reflecting strong cash conversion. 
- Total debt outstanding is $9.2 billion, with a weighted average duration of 13 years and 3.2x debt-to-EBITDA ratio. 
- Share buybacks and dividends returned $1.5 billion to shareholders in the first 9 months of 2025. 

**【Q&A Highlights】**
- **China Strategy**: Planning to capitalize on out-licensing trends, with multiple teams engaged in building relationships with Chinese biotech companies. 
- **LP(a) Trials**: Novartis' pelacarsen and Amgen's olpasiran Phase III trials remain on track, with potential for multibillion-dollar franchise. 
- **Synthetic Royalties**: Obesity space is under active evaluation, but company remains disciplined in pursuing only high-impact opportunities. 
- **Competitive Landscape**: Royalty Pharma's perpetual capital structure and long-term holding strategy differentiate it from private equity competitors. 

Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript

Financial Royalty Assets

Intangible Royalty Assets

Other Royalty Income

RPRX

RPRX fundamentals

You can ask Aime